Effect of four-week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes

被引:87
作者
Pavlovic, D
Kocic, R
Kocic, G
Jevtovic, T
Radenkovic, S
Mikic, D
Stojanovic, M
Djordjevic, PB
机构
[1] Fac Med Nis, Inst Biochem, YU-18000 Nish, Yugoslavia
[2] Fac Med Nis, Endocrinol Clin, YU-18000 Nish, Yugoslavia
[3] Fac Med Belgrade, Inst Endocrinol, YU-11000 Belgrade, Yugoslavia
关键词
metformin; diabetes mellitus; oxidative stress; antioxidative defense enzymes;
D O I
10.1046/j.1463-1326.2000.00089.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The principal metabolic effect of metformin-an oral antihyperglycaemic agent-is the improvement in the sensitivity of peripheral tissues and liver to insulin. This study examined the effect of metformin monotherapy on antioxidative defence system activity in erythrocytes and plasma in diabetic patients. We studied the effect of metformin treatment on the activities of Cu, Zn-superoxide dismutase (EC 1. 15. 1. 1.), catalase (EC 1. 11. 1. 6.) and glutathione peroxidase (EC 1. 11. 1. 9.) in relation to lipid peroxidation products and reduced glutathione level in plasma and erythrocytes. In this study we also examined erythrocytes' susceptibility to H2O2-induced oxidative stress during metformin therapy. Although metformin monotherapy ameliorated the imbalance between free radical-induced increase in lipid peroxidation (by reducing the MDA level in both erythrocytes and plasma) and decreased plasma and cellular antioxidant defences (by increasing the erythrocyte activities of Cu, Zn, SOD, catalase and GSH level) and decreased erythrocyte susceptibility to oxidative stress, it had negligible effect to scavenge Fe ion-induced free radical generation in a phospholipid-liposome system.
引用
收藏
页码:251 / 256
页数:6
相关论文
共 39 条
[1]  
AMMON HPT, 1989, DIABETOLOGIA, V32, P797
[2]  
ANDREEVA LI, 1988, LAB DELO, P41
[3]  
AWASTHI YC, 1975, J BIOL CHEM, V250, P5144
[4]   BIGUANIDES AND NIDDM [J].
BAILEY, CJ .
DIABETES CARE, 1992, 15 (06) :755-772
[5]   Drug therapy - Metformin [J].
Bailey, CJ ;
Turner, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (09) :574-579
[6]  
BEUTLER E, 1963, J LAB CLIN MED, V61, P882
[7]  
Beutler E., 1982, Red Cell Metabolism, P105
[8]   HYDROPEROXIDE ANION, HO2-, IS AN AFFINITY REAGENT FOR THE INACTIVATION OF YEAST CU,ZN SUPEROXIDE-DISMUTASE - MODIFICATION OF ONE HISTIDINE PER SUBUNIT [J].
BLECH, DM ;
BORDERS, CL .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1983, 224 (02) :579-586
[9]  
Clark J., 1977, EXP BIOCH, P187, DOI [10.1080/10826076.2014.962148, DOI 10.1080/10826076.2014.962148]
[10]   AMINOGUANIDINE, A NOVEL INHIBITOR OF NITRIC-OXIDE FORMATION, PREVENTS DIABETIC VASCULAR DYSFUNCTION [J].
CORBETT, JA ;
TILTON, RG ;
CHANG, K ;
HASAN, KS ;
IDO, Y ;
WANG, JL ;
SWEETLAND, MA ;
LANCASTER, JR ;
WILLIAMSON, JR ;
MCDANIEL, ML .
DIABETES, 1992, 41 (04) :552-556